小梁骨评分(TBS)在骨质疏松管理中的临床应用更新:欧洲骨质疏松、骨关节炎和肌肉骨骼疾病临床与经济方面学会(ESCEO)和国际骨质疏松基金会(IOF)专家小组会议结果,由世界卫生组织肌肉骨骼流行病学合作中心支持
该立场文件由ESCEO和IOF专家工作组系统综述96篇文章,更新TBS在骨折预测和治疗监测中的证据,并采用GRADE方法形成专家共识声明。更新证据显示TBS联合FRAX和/或BMD可增强原发性和继发性骨质疏松的骨折风险预测,并有助于治疗决策和监测。所有共识声明均投票为强烈推荐。
要点
- TBS联合FRAX和/或BMD可增强原发性和继发性骨质疏松的骨折风险预测。
- TBS可结合BMD和临床危险因素为治疗启动和抗骨质疏松药物选择提供信息。
- TBS可为长期地舒单抗和促骨形成药物治疗监测提供有用的辅助信息。
核心结论
- 将TBS评估加入FRAX和/或BMD可增强原发性和继发性骨质疏松的骨折风险预测,为治疗决策和监测增加有用信息。
- 本文提供的专家共识声明可用于指导TBS在骨质疏松评估和管理临床实践中的整合,附录提供了操作方法的示例。
研究设计与样本
- 由ESCEO召集专家工作组,并由IOF支持,对证据进行系统综述,针对TBS潜在应用的四个关键主题制定检索策略:男性和女性骨折预测、绝经后骨质疏松的治疗启动和监测、继发性骨质疏松的骨折预测、继发性骨质疏松的治疗监测。
- 共综述96篇文章,纳入来自20多个国家的关于TBS用于男性和女性骨折预测的数据。
- 指导TBS临床使用的声明源自综述,并采用推荐分级的评估、制定与评价(GRADE)方法通过共识进行分级。
主要发现
- 更新证据显示TBS增强原发性和继发性骨质疏松的骨折风险预测。
- TBS与BMD和临床危险因素结合时,可为治疗启动和抗骨质疏松治疗选择提供信息。
- 证据还表明TBS在长期地舒单抗和促骨形成药物治疗监测中提供有用的辅助信息。
关键数值与推荐
- 所有专家共识声明均投票为强烈推荐。
临床怎么用
- 本文提供的专家共识声明可指导TBS在临床实践中用于骨质疏松的评估和管理。
- 附录提供了操作方法的示例。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Trabecular bone score (TBS) is a grey-level textural measurement acquired from dual-energy X-ray absorptiometry lumbar spine images and is a validated index of bone microarchitecture. In 2015, a Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) published a review of the TBS literature, concluding that TBS predicts hip and major osteoporotic fracture, at least partly independent of bone mineral density (BMD) and clinical risk factors. It was also concluded that TBS is potentially amenable to change as a result of pharmacological therapy. Further evidence on the utility of TBS has since accumulated in both primary and secondary osteoporosis, and the introduction of FRAX and BMD T-score adjustment for TBS has accelerated adoption. This position paper therefore presents a review of the updated scientific literature and provides expert consensus statements and corresponding operational guidelines for the use of TBS. METHODS: An Expert Working Group was convened by the ESCEO and a systematic review of the evidence undertaken, with defined search strategies for four key topics with respect to the potential use of TBS: (1) fracture prediction in men and women; (2) initiating and monitoring treatment in postmenopausal osteoporosis; (3) fracture prediction in secondary osteoporosis; and (4) treatment monitoring in secondary osteoporosis. Statements to guide the clinical use of TBS were derived from the review and graded by consensus using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach. RESULTS: A total of 96 articles were reviewed and included data on the use of TBS for fracture prediction in men and women, from over 20 countries. The updated evidence shows that TBS enhances fracture risk prediction in both primary and secondary osteoporosis, and can, when taken with BMD and clinical risk factors, inform treatment initiation and the choice of antiosteoporosis treatment. Evidence also indicates that TBS provides useful adjunctive information in monitoring treatment with long-term denosumab and anabolic agents. All expert consensus statements were voted as strongly recommended. CONCLUSION: The addition of TBS assessment to FRAX and/or BMD enhances fracture risk prediction in primary and secondary osteoporosis, adding useful information for treatment decision-making and monitoring. The expert consensus statements provided in this paper can be used to guide the integration of TBS in clinical practice for the assessment and management of osteoporosis. An example of an operational approach is provided in the appendix. This position paper presents an up-to-date review of the evidence base, synthesised through expert consensus statements, which informs the implementation of Trabecular Bone Score in clinical practice.
引用
- Shevroja E, Reginster JY, Lamy O, et al. Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging. Osteoporos Int. 2023. PMID: 37393412. doi:10.1007/s00198-023-06817-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。